Archives of Dermatological Research

, Volume 304, Issue 2, pp 87–113 | Cite as

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

  • A. NastEmail author
  • W. H. Boehncke
  • U. Mrowietz
  • H. M. Ockenfels
  • S. Philipp
  • K. Reich
  • T. Rosenbach
  • A. Sammain
  • M. Schlaeger
  • M. Sebastian
  • W. Sterry
  • V. Streit
  • M. Augustin
  • R. Erdmann
  • J. Klaus
  • J. Koza
  • S. Müller
  • H. D. Orzechowski
  • S. Rosumeck
  • G. Schmid-Ott
  • T. Weberschock
  • B. Rzany


Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance (Richards et al. in J Am Acad Dermatol 41(4):581–583, 1999). To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis first published in 2006 and now updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. This short version of the guidelines presents the resulting series of therapeutic recommendations, which were based on a systematic literature search and discussed and approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs, as well as detailed information on how best to apply the treatments described (for full version please see Nast et al. in JDDG Suppl 2:S1–S104, 2011 or


Evidence-based guidelines Psoriasis vulgaris Treatment 



The update of the guidelines was generated upon request by the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD). The project was supported by the ‘Förderverein der Deutschen Dermatologischen Gesellschaft’, the funding body of the DDG.

Conflict of interest

The documentation and disclosure of potential conflicts of interest was based on the standardized form “Declaration of Conflicts of Interest” provided by the AWMF. The completed forms are available online at Given the diversity of the members of the guidelines group, it is assumed that any potential conflicts of interest balance each other out.


  1. 1.
    Abe M, Ishibuchi H, Syuto T, Sogabe Y, Yokoyama Y, Ishikawa O (2007) Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris. J Dermatol 34(5):290–293. doi: 10.1111/j.1346-8138.2007.00275.x PubMedCrossRefGoogle Scholar
  2. 2.
    Abe M, Syuto T, Hasegawa M, Sogabe Y, Yokoyama Y, Ishikawa O (2006) Daily versus intermittent application of high-concentration tacalcitol ointment in combination with low-dose cyclosporin for psoriasis vulgaris. J Dermatol 33(2):108–111. doi: 10.1111/j.1346-8138.2006.00022.x PubMedCrossRefGoogle Scholar
  3. 3.
    Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B (2002) A novel liposomal formulation of dithranol for psoriasis: preliminary results. J Dermatol 29(8):529–532PubMedGoogle Scholar
  4. 4.
    Agrup G, Agdell J (1985) A comparison between Antraderm stick (0.5 and 1%) and dithranol paste (0.125 and 0.25%) in the treatment of psoriasis. Br J Clin Pract 39(5):185–187PubMedGoogle Scholar
  5. 5.
    Altmeyer P, Hartwig R, Matthes U (1996) Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. Hautarzt 47(3):190–196PubMedCrossRefGoogle Scholar
  6. 6.
    Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G et al (1994) Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30(6):977–981PubMedCrossRefGoogle Scholar
  7. 7.
    Amornpinyokeit N, Asawanonda P (2006) 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed 22(6):285–289. doi: 10.1111/j.1600-0781.2006.00249.x PubMedCrossRefGoogle Scholar
  8. 8.
    Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J (2007) Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res 298(10):479–483. doi: 10.1007/s00403-006-0723-8 PubMedCrossRefGoogle Scholar
  9. 9.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157. doi: 10.1136/ard.2004.032268 PubMedCrossRefGoogle Scholar
  10. 10.
    Asawanonda P, Amornpinyokeit N, Nimnuan C (2008) Topical 8-methoxypsoralen enhances the therapeutic results of targeted narrowband ultraviolet B phototherapy for plaque-type psoriasis. J Eur Acad Dermatol Venereol 22(1):50–55. doi: 10.1111/j.1468-3083.2007.02328.x PubMedGoogle Scholar
  11. 11.
    Asawanonda P, Nateetongrungsak Y (2006) Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 54(6):1013–1018. doi: 10.1016/j.jaad.2006.01.004 PubMedCrossRefGoogle Scholar
  12. 12.
    Bagatell F (1988) Management of psoriasis: a clinical evaluation of the dermatological patch, Actiderm™, over a topical steroid. Adv Therap 5(6):291–296Google Scholar
  13. 13.
    Bagel J (2009) LCD plus NB-UVB reduces time to improvement of psoriasis vs NB-UVB alone. J Drugs Dermatol 8(4):351–357PubMedGoogle Scholar
  14. 14.
    Barth J, Dietz O, Heilmann S, Kadner H, Kraensel H, Meffert H, Metz D, Pinzer B, Schiller F (1978) Photochemotherapy by 8-methoxypsoralen and UVA in psoriasis vulgaris—clinical experiences in 5 dermatological departments of GDR. Dermatol Monatsschr 164(6):401–407 (author’s translation)PubMedGoogle Scholar
  15. 15.
    Bayard W, Hunziker T, Krebs A, Speiser P, Joshi R (1987) Peroral long-term treatment of psoriasis using fumaric acid derivatives. Hautarzt 38(5):279–285PubMedGoogle Scholar
  16. 16.
    Belsito DV, Kechijian P (1982) The role of tar in Goeckerman therapy. Arch Dermatol 118(5):319–321PubMedCrossRefGoogle Scholar
  17. 17.
    Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM (2007) Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatolog Treat 18(2):76–83. doi: 10.1080/09546630601121086 PubMedCrossRefGoogle Scholar
  18. 18.
    Berg M, Ros AM (1994) Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 10(5):217–220PubMedGoogle Scholar
  19. 19.
    Berger K, Ehlken B, Kugland B, Augustin M (2005) Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 3(7):511–518. doi: 10.1111/j.1610-0387.2005.05729.x PubMedCrossRefGoogle Scholar
  20. 20.
    Beutner K, Chakrabarty A, Lemke S, Yu K (2006) An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 5(4):357–360PubMedGoogle Scholar
  21. 21.
    Bongiorno MR, Pistone G, Doukaki S, Arico M (2008) Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther 21(Suppl 2):S15–S20. doi: 10.1111/j.1529-8019.2008.00227.x Google Scholar
  22. 22.
    Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V, Borroni G (2005) Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: “right-left intra-individual pre/post comparison design”. Int J Immunopathol Pharmacol 18(4):755–760PubMedGoogle Scholar
  23. 23.
    Brockow T, Schiener R, Franke A, Resch KL, Peter RU (2007) A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis. J Altern Complement Med 13(7):725–732. doi: 10.1089/acm.2007.7099 PubMedCrossRefGoogle Scholar
  24. 24.
    Brockow T, Schiener R, Franke A, Resch KL, Peter RU (2007) A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 21(8):1027–1037. doi: 10.1111/j.1468-3083.2007.02152.x PubMedCrossRefGoogle Scholar
  25. 25.
    Buckley DA, Healy E, Rogers S (1995) A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. Br J Dermatol 133(3):417–422PubMedCrossRefGoogle Scholar
  26. 26.
    Caca-Biljanovska NG, V’Lckova-Laskoska MT (2002) Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J 43(6):707–712PubMedGoogle Scholar
  27. 27.
    Calzavara-Pinton P (1998) Narrow band UVB (311 nm) phototherapy and PUVA photochemotherapy: a combination. J Am Acad Dermatol 38(5 Pt 1):687–690 (pii:S0190-9622(98)70214-2)PubMedCrossRefGoogle Scholar
  28. 28.
    Calzavara-Pinton P, Ortel B, Carlino A, Honigsmann H, De Panfilis G (1992) A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1(1):46–51PubMedCrossRefGoogle Scholar
  29. 29.
    Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G (1994) Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 189(3):256–259PubMedCrossRefGoogle Scholar
  30. 30.
    Camarasa JM, Ortonne JP, Dubertret L (2003) Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 14(1):8–13 (pii:EPP1D2VMP79MR4VG)PubMedCrossRefGoogle Scholar
  31. 31.
    Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A (2009) Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 22(2):371–377PubMedGoogle Scholar
  32. 32.
    Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29(2):210–214. doi: 10.1007/s10875-008-9233-0 PubMedCrossRefGoogle Scholar
  33. 33.
    Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S (2004) Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 15(1):23–26. doi: 10.1080/09541440042000269 PubMedCrossRefGoogle Scholar
  34. 34.
    Carlin CS, Callis KP, Krueger GG (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139(4):436–442. doi: 10.1001/archderm.139.4.436 PubMedCrossRefGoogle Scholar
  35. 35.
    Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR (2005) Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 141(1):43–46. doi: 10.1001/archderm.141.1.43 PubMedCrossRefGoogle Scholar
  36. 36.
    Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA (2006) Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 19(1):225–229PubMedGoogle Scholar
  37. 37.
    Cassano N, Miracapillo A, Coviello C, Loconsole F, Bellino M, Vena GA (2006) Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig 26(4):227–233PubMedCrossRefGoogle Scholar
  38. 38.
    Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA (2007) Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. Int J Immunopathol Pharmacol 20(3):647–650PubMedGoogle Scholar
  39. 39.
    Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A (2007) Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 21:1203–1208PubMedGoogle Scholar
  40. 40.
    Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271):1842–1847. doi: 10.1016/S0140-6736(00)04954-0 PubMedCrossRefGoogle Scholar
  41. 41.
    Chladek J, Simkova M, Vaneckova J, Hroch M, Chladkova J, Martinkova J, Vavrova J, Beranek M (2008) The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 64(4):347–355. doi: 10.1007/s00228-007-0442-x PubMedCrossRefGoogle Scholar
  42. 42.
    Chuang TY, Samson CR (1991) Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone ointment for psoriasis—a multicentre, randomized, double-blinded study. J Dermatol Treat 2(2):63–66CrossRefGoogle Scholar
  43. 43.
    Cohen AD, Shapiro J, Michael D, Hodak E, Van-Dijk D, Naggan L, Vardy DA (2008) Outcome of “short-term” Dead Sea climatotherapy for psoriasis. Acta Derm Venereol 88(1):90–91. doi: 10.2340/00015555-0340 PubMedCrossRefGoogle Scholar
  44. 44.
    Collins P, Rogers S (1992) Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 127(4):392–395PubMedCrossRefGoogle Scholar
  45. 45.
    Cooper EJ, Herd RM, Priestley GC, Hunter JA (2000) A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 25(2):111–114. doi: ced589[pii] PubMedCrossRefGoogle Scholar
  46. 46.
    Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S (2005) Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 152(1):187–189. doi: 10.1111/j.1365-2133.2005.06306.x PubMedCrossRefGoogle Scholar
  47. 47.
    Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG (1997) Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 133(12):1514–1522PubMedCrossRefGoogle Scholar
  48. 48.
    De Leeuw J, Van Lingen RG, Both H, Tank B, Nijsten T, Martino Neumann HA (2009) A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis. Dermatol Surg 35(1):80–91. doi: 10.1111/j.1524-4725.2008.34386.x PubMedCrossRefGoogle Scholar
  49. 49.
    de Mare S, Calis N, den Hartog G, van Erp PE, van de Kerkhof PC (1988) The relevance of salicylic acid in the treatment of plaque psoriasis with dithranol creams. Skin Pharmacol 1(4):259–264PubMedCrossRefGoogle Scholar
  50. 50.
    Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S (2004) Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 74(3):201–206PubMedGoogle Scholar
  51. 51.
    Diel R, Hauer B, Loddenkemper R, Manger B, Kruger K (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 68(5):411–416. doi: 10.1007/s00393-009-0475-x PubMedCrossRefGoogle Scholar
  52. 52.
    Diette KM, Momtaz K, Stern RS, Arndt KA, Parrish JA (1984) Role of ultraviolet A in phototherapy for psoriasis. J Am Acad Dermatol 11(3):441–447PubMedCrossRefGoogle Scholar
  53. 53.
    Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82(2):131–135PubMedCrossRefGoogle Scholar
  54. 54.
    Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS (1989) Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 20(5 Pt 1):748–754PubMedCrossRefGoogle Scholar
  55. 55.
    Elder CA, Moore M, Chang CT, Jin J, Charnick S, Nedelman J, Cohen A, Guzzo C, Lowe N, Simpson K et al (1995) Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 35(9):865–875PubMedGoogle Scholar
  56. 56.
    Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG et al (1991) Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324(5):277–284PubMedCrossRefGoogle Scholar
  57. 57.
    Engst R, Huber J (1989) Results of cyclosporin treatment of severe, chronic psoriasis vulgaris. Hautarzt 40(8):486–489PubMedGoogle Scholar
  58. 58.
    Erceg A, Bovenschen HJ, van de Kerkhof PC, Seyger MM (2006) Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative study. Br J Dermatol 155(1):110–114. doi: 10.1111/j.1365-2133.2006.07141.x PubMedCrossRefGoogle Scholar
  59. 59.
    Ezquerra GM, Regana MS, Millet PU (2007) Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis. Acta Derm Venereol 87(5):449–450. doi: 10.2340/00015555-0290 PubMedCrossRefGoogle Scholar
  60. 60.
    Fabry H, Yawalkar SJ (1983) A comparative multicentre trial of halometasone ointment and fluocortolone plus fluocortolone caproate ointment in the treatment of psoriasis. J Int Med Res 11(Suppl 1):26–30PubMedGoogle Scholar
  61. 61.
    Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL (2002) Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 46(6):900–906PubMedCrossRefGoogle Scholar
  62. 62.
    Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD (1989) Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 21(1):91–97PubMedCrossRefGoogle Scholar
  63. 63.
    Finzi AF, Mozzanica N, Pigatto PD, Cattaneo A, Ippolito F (1993) Cyclosporine versus etretinate: Italian multicentre comparative trial in severe psoriasis. Dermatology 187(Suppl 1):8–18CrossRefGoogle Scholar
  64. 64.
    Fleischer AB Jr, Clark AR, Rapp SR, Reboussin DM, Feldman SR (1997) Commercial tanning bed treatment is an effective psoriasis treatment: results from an uncontrolled clinical trial. J Invest Dermatol 109(2):170–174PubMedCrossRefGoogle Scholar
  65. 65.
    Flytström I, Stenberg B, Svensson A, Bergbrant IM (2008) Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 158(1):116–121. doi: 10.1111/j.1365-2133.2007.08284.x PubMedGoogle Scholar
  66. 66.
    Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE (2002) A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol 146(3):458–465. doi: 4622[pii] PubMedCrossRefGoogle Scholar
  67. 67.
    Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF (2004) Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol 17(3):401–406PubMedGoogle Scholar
  68. 68.
    Frappaz A, Thivolet J (1993) Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol 3:351–354Google Scholar
  69. 69.
    Frost P, Horwitz SN, Caputo RV, Berger SM (1979) Tar gel-phototherapy for psoriasis. Combined therapy with suberythemogenic doses of fluorescent sunlamp ultraviolet radiation. Arch Dermatol 115(7):840–846PubMedCrossRefGoogle Scholar
  70. 70.
    Gisondi P, Del Giglio M, Cotena C, Girolomoni G (2008) Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 158(6):1345–1349. doi: 10.1111/j.1365-2133.2008.08564.x PubMedCrossRefGoogle Scholar
  71. 71.
    Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G (2008) Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 88(5):1242–1247PubMedGoogle Scholar
  72. 72.
    Goldinger SM, Dummer R, Schmid P, Prinz Vavricka M, Burg G, Lauchli S (2006) Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology 213(2):134–139. doi: 10.1159/000093852 PubMedCrossRefGoogle Scholar
  73. 73.
    Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002) Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205(1):46–53PubMedCrossRefGoogle Scholar
  74. 74.
    Gollnick H, Menter A (1999) Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 140(Suppl 54):18–23PubMedCrossRefGoogle Scholar
  75. 75.
    Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55(4):598–606. doi: 10.1016/j.jaad.2006.05.027 PubMedCrossRefGoogle Scholar
  76. 76.
    Gordon PM, Diffey BL, Mattews JNS, Farr PM (1999) A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 41:728–732PubMedCrossRefGoogle Scholar
  77. 77.
    Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664):633–640. doi: 10.1016/S0140-6736(09)60140-9 PubMedCrossRefGoogle Scholar
  78. 78.
    Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51(4):534–542. doi: 10.1016/j.jaad.2004.02.021 PubMedCrossRefGoogle Scholar
  79. 79.
    Gottlieb AB, Ford RO, Spellman MC (2003) The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 7(3):185–192. doi: 10.1007/s10227-002-0114-5 PubMedCrossRefGoogle Scholar
  80. 80.
    Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139(12):1627–1632. doi: 10.1001/archderm.139.12.1627 (discussion 1632)PubMedCrossRefGoogle Scholar
  81. 81.
    Green L, Sadoff W (2002) A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 6(2):95–102. doi: 10.1007/s10227-001-0031-z PubMedCrossRefGoogle Scholar
  82. 82.
    Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M et al (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31(1):68–74PubMedCrossRefGoogle Scholar
  83. 83.
    Grundmann-Kollmann M, Ludwig R, Zollner TM, Ochsendorf F, Thaci D, Boehncke WH, Krutmann J, Kaufmann R, Podda M (2004) Narrowband UVB and cream psoralen–UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol 50(5):734–739. doi: 10.1016/S0190 PubMedCrossRefGoogle Scholar
  84. 84.
    Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147(2):316–323PubMedCrossRefGoogle Scholar
  85. 85.
    Guenther LC, Poulin YP, Pariser DM (2000) A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 22(10):1225–1238PubMedCrossRefGoogle Scholar
  86. 86.
    Gupta AK, Goldfarb MT, Ellis CN, Voorhees JJ (1989) Side-effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 20(6):1088–1093PubMedCrossRefGoogle Scholar
  87. 87.
    Hacker SM, Rasmussen JE (1992) The effect of flash lamp-pulsed dye laser on psoriasis. Arch Dermatol 128(6):853–855PubMedCrossRefGoogle Scholar
  88. 88.
    Halevy S, Giryes H, Friger M, Sukenik H (1997) Dead sea bath salt for the treatment of psoriasis vulgaris: a double-blind controlled study. J Eur Acad Dermatol Venereol 9(3):237–242CrossRefGoogle Scholar
  89. 89.
    Hanke CW, Steck WD, Roenigk HH Jr (1979) Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol 115(9):1074–1077PubMedCrossRefGoogle Scholar
  90. 90.
    Harari M, Novack L, Barth J, David M, Friger M, Moses SW (2007) The percentage of patients achieving PASI 75 after 1 month and remission time after climatotherapy at the Dead Sea. Int J Dermatol 46(10):1087–1091. doi: 10.1111/j.1365-4632.2007.03278.x PubMedCrossRefGoogle Scholar
  91. 91.
    Hashizume H, Ito T, Yagi H, Takigawa M, Kageyama H, Furukawa F, Hata M, Shirahama S, Tanaka M, Higashishiba T, Machida H, Tsushima T, Matsushita K (2007) Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol 34(7):430–434. doi: 10.1111/j.1346-8138.2007.00305.x PubMedCrossRefGoogle Scholar
  92. 92.
    Henseler T, Wolff K, Honigsmann H, Christophers E (1981) Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1(8225):853–857PubMedCrossRefGoogle Scholar
  93. 93.
    Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349(7):658–665. doi: 10.1056/NEJMoa021359 PubMedCrossRefGoogle Scholar
  94. 94.
    Higgins E, Munro C, Marks J, Friedmann PS, Shuster S (1989) Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 121(1):71–74PubMedCrossRefGoogle Scholar
  95. 95.
    Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR (2003) The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 49(1):79–82. doi: 10.1067/mjd.2003.417 PubMedCrossRefGoogle Scholar
  96. 96.
    Housman TS, Pearce DJ, Feldman SR (2004) A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 15(2):94–97. doi: 10.1080/09546630310021947 PubMedCrossRefGoogle Scholar
  97. 97.
    Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J (2008) A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 22(1):19–24. doi: 10.1111/j.1468-3083.2007.02264.x PubMedGoogle Scholar
  98. 98.
    Hutchinson PE, Marks R, White J (2000) The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 201(2):139–145PubMedCrossRefGoogle Scholar
  99. 99.
    Ilknur T, Akarsu S, Aktan S, Ozkan S (2006) Comparison of the effects of pulsed dye laser, pulsed dye laser + salicylic acid, and clobetasole propionate + salicylic acid on psoriatic plaques. Dermatol Surg 32(1):49–55PubMedCrossRefGoogle Scholar
  100. 100.
    Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, Yu K (2006) Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 78(5):348–354PubMedGoogle Scholar
  101. 101.
    Kabat-Zinn J, Wheeler E, Light T, Skillings A, Scharf MJ, Cropley TG, Hosmer D, Bernhard JD (1998) Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 60(5):625–632PubMedGoogle Scholar
  102. 102.
    Katugampola GA, Rees AM, Lanigan SW (1995) Laser treatment of psoriasis. Br J Dermatol 133(6):909–913PubMedCrossRefGoogle Scholar
  103. 103.
    Katz HI, Tanner DJ, Cuffie CA, Brody NI, Garcia CJ, Lowe NJ, Medansky RS, Roth HL, Shavin JS, Swinyer LJ (1998) A comparison of the efficacy and safety of the combination mometasone furoate 0.1%/salicylic acid 5% ointment with each of its components in psoriasis. J Derm Treat 9(3):151–156CrossRefGoogle Scholar
  104. 104.
    Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B (2002) A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205(4):389–393PubMedCrossRefGoogle Scholar
  105. 105.
    Kaur J, Sharma VK, Sethuraman G, Tejasvi T (2008) Comparison of the efficacy of psoralen ultraviolet A with narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis in patients with skin types IV and V. Clin Exp Dermatol 33(4):513–515. doi: 10.1111/j.1365-2230.2008.02718.x PubMedCrossRefGoogle Scholar
  106. 106.
    Kaur M, Oliver B, Hu J, Feldman SR (2006) Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis 78(3):200–203PubMedGoogle Scholar
  107. 107.
    Khurshid K, Haroon TS, Hussain I, Pal SS, Jahangir M, Zaman T (2000) Psoralen-ultraviolet A therapy vs. psoralen-ultraviolet B therapy in the treatment of plaque-type psoriasis: our experience with Fitzpatrick skin type IV. Int J Dermatol 39(11):865–867PubMedCrossRefGoogle Scholar
  108. 108.
    Kirby B, Buckley DA, Rogers S (1999) Large increments in psoralen–ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. Br J Dermatol 140(4):661–666PubMedCrossRefGoogle Scholar
  109. 109.
    Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR (2008) Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 7(3):245–253PubMedGoogle Scholar
  110. 110.
    Koc E, Tunca M, Akgul EO, Akar A, Kurt Y, Kurumlu Z, Erbil K, Kilic S (2009) Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. J Dermatol 36(4):191–196. doi: 10.1111/j.1346-8138.2009.00622.x PubMedCrossRefGoogle Scholar
  111. 111.
    Kolbach DN, Nieboer C (1992) Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 27(5 Pt 1):769–771PubMedCrossRefGoogle Scholar
  112. 112.
    Koo J, Blum RR, Lebwohl M (2006) A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 55(4):637–641. doi: 10.1016/j.jaad.2006.05.026 PubMedCrossRefGoogle Scholar
  113. 113.
    Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, Edwards L, Breneman DL, Piacquadio DJ, Guzzo CA, Monroe EW (1998) Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20(2):283–291PubMedCrossRefGoogle Scholar
  114. 114.
    Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR (2000) Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 43(5 Pt 1):821–828. doi: 10.1067/mjd.2000.107940 PubMedCrossRefGoogle Scholar
  115. 115.
    Koo JY, Martin D (2001) Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 40(3):210–212PubMedCrossRefGoogle Scholar
  116. 116.
    Korver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, van De Kerkhof PC (2007) A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol 156(1):130–137. doi: 10.1111/j.1365-2133.2006.07561.x PubMedCrossRefGoogle Scholar
  117. 117.
    Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T et al (1989) A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 69(1):35–40PubMedGoogle Scholar
  118. 118.
    Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM (2004) Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 150(6):1167–1173. doi: 10.1111/j.1365-2133.2004.05986.x PubMedCrossRefGoogle Scholar
  119. 119.
    Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L (1994) Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 130(3):366–375PubMedCrossRefGoogle Scholar
  120. 120.
    Lago E, Carneiro S, Cuzzi T, Magalhaes G, Cassia F, Pessanha F, Ramos-e-Silva M (2007) Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. J Cutan Pathol 34(1):15–21. doi: 10.1111/j.1600-0560.2006.00571.x PubMedCrossRefGoogle Scholar
  121. 121.
    Lebwohl M (2000) Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 43(2 Pt 3):S43–S46PubMedCrossRefGoogle Scholar
  122. 122.
    Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR (2002) A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 41(5):269–274PubMedCrossRefGoogle Scholar
  123. 123.
    Lebwohl M, Yoles A, Lombardi K, Lou W (1998) Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39(3):447–450PubMedCrossRefGoogle Scholar
  124. 124.
    Lee CS, Koo J (2009) The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. J Drugs Dermatol 8(8):751–755PubMedGoogle Scholar
  125. 125.
    Leenutaphong V, Nimkulrat P, Sudtim S (2000) Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed 16(5):202–206PubMedCrossRefGoogle Scholar
  126. 126.
    Lemme G, Campanati A, Paolinelli M, Offidani A (2007) Diffuse psoriasis plaque type and infliximab: our experience and review of literature. G Ital Dermatol Venereol 142:9–14Google Scholar
  127. 127.
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4 PubMedCrossRefGoogle Scholar
  128. 128.
    Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349(21):2014–2022. doi: 10.1056/NEJMoa030409 PubMedCrossRefGoogle Scholar
  129. 129.
    Levell NJ, Shuster S, Munro CS, Friedmann PS (1995) Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 75(1):65–69PubMedGoogle Scholar
  130. 130.
    LeVine MJ, Parrish JA (1982) The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 78(2):157–159PubMedCrossRefGoogle Scholar
  131. 131.
    Liao YH, Chiu HC, Tseng YS, Tsai TF (2007) Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(−1) ointment and tacrolimus 0.3 mg g(−1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 157(5):1005–1012. doi: 10.1111/j.1365-2133.2007.08201.x PubMedCrossRefGoogle Scholar
  132. 132.
    Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B (2003) Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol 148(3):444–451PubMedCrossRefGoogle Scholar
  133. 133.
    Lotti T, Tripo L, Grazzini M, Krysenka A, Buggiani G, De Giorgi V (2009) Focused UV-B narrowband microphototherapy (Biopsorin). A new treatment for plaque psoriasis. Dermatol Ther 22(4):383–385. doi: 10.1111/j.1529-8019.2009.01250.x PubMedCrossRefGoogle Scholar
  134. 134.
    Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, Foley V, Soto P (2005) Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 16(3):158–164. doi: 10.1080/09546630510041060 PubMedCrossRefGoogle Scholar
  135. 135.
    Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB (2006) A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 54(1):115–118. doi: 10.1016/j.jaad.2005.09.012 PubMedCrossRefGoogle Scholar
  136. 136.
    Mahrle G, Schulze HJ (1990) The effect of initial external glucocorticoid administration on cignolin treatment of psoriasis. Z Hautkr 65(3):282, 285–287Google Scholar
  137. 137.
    Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK (1995) Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 32(1):78–88PubMedCrossRefGoogle Scholar
  138. 138.
    Markham T, Rogers S, Collins P (2003) Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 139(3):325–328PubMedCrossRefGoogle Scholar
  139. 139.
    Martin-Ezquerra G, Sanchez-Regana M, Umbert-Millet P (2007) Optimization of narrow-band uvb with a 5% oleic acid cream in the treatment of psoriasis. J Drugs Dermatol 6(3):290–292PubMedGoogle Scholar
  140. 140.
    Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Umbert Millet P (2006) Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 5(4):334–336PubMedGoogle Scholar
  141. 141.
    McBride SR, Walker P, Reynolds NJ (2003) Optimizing the frequency of outpatient short-contact dithranol treatment used in combination with broadband ultraviolet B for psoriasis: a randomized, within-patient controlled trial. Br J Dermatol 149(6):1259–1265PubMedCrossRefGoogle Scholar
  142. 142.
    Medansky RS, Cuffie CA, Tanner DJ (1997) Mometasone furoate 0.1%-salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther 19(4):701–709PubMedCrossRefGoogle Scholar
  143. 143.
    Meffert H, Brautigam M, Farber L, Weidinger G (1997) Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. Acta Derm Venereol 77(2):137–141PubMedGoogle Scholar
  144. 144.
    Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW (2009) Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 8(1):52–57PubMedGoogle Scholar
  145. 145.
    Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB (2007) A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56(1):31 e31–e15. doi: 10.1016/j.jaad.2006.07.017 Google Scholar
  146. 146.
    Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K (2008) Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58(1):106–115. doi: 10.1016/j.jaad.2007.09.010 PubMedCrossRefGoogle Scholar
  147. 147.
    Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S (2009) Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch Dermatol 145(4):387–393. doi: 10.1001/archdermatol.2009.5 PubMedCrossRefGoogle Scholar
  148. 148.
    Monastirli A, Georgiou S, Pasmatzi E, Sakkis T, Badavanis G, Drainas D, Sagriotis A, Tsambaos D (2002) Calcipotriol plus short-contact dithranol: a novel topical combination therapy for chronic plaque psoriasis. Skin Pharmacol Appl Skin Physiol 15(4):246–251PubMedGoogle Scholar
  149. 149.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR (2007) A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 56(4):598–603. doi: 10.1016/j.jaad.2006.09.002 PubMedCrossRefGoogle Scholar
  150. 150.
    Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB (1982) Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 6(1):46–51PubMedCrossRefGoogle Scholar
  151. 151.
    Mrowietz U, Christophers E, Altmeyer P (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138(3):456–460PubMedCrossRefGoogle Scholar
  152. 152.
    Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2011) S3-guidelines for the treatment of psoriasis vulgaris. Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104. doi: 10.1111/j.1610-0379.2011.07680.x PubMedGoogle Scholar
  153. 153.
    Nast A, Erdmann R, Pathirana D, Rzany B (2008) Translating psoriasis treatment guidelines into clinical practice—the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 14(5):803–806. doi: 10.1111/j.1365-2753.2008.00971.x PubMedCrossRefGoogle Scholar
  154. 154.
    Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299(3):111–138. doi: 10.1007/s00403-007-0744-y PubMedCrossRefGoogle Scholar
  155. 155.
    Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2006) S3-Guidelines for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl 2):S1–S126. doi: 10.1111/j.1610-0387.2006.06172.x PubMedGoogle Scholar
  156. 156.
    Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B (2008) Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 22(11):1337–1342. doi: 10.1111/j.1468-3083.2008.02841.x PubMedCrossRefGoogle Scholar
  157. 157.
    Nevitt GJ, Hutchinson PE (1996) Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol 135(4):533–537PubMedCrossRefGoogle Scholar
  158. 158.
    Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D (1990) Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study. Ned Tijdschr Geneeskd 134(49):2387–2391PubMedGoogle Scholar
  159. 159.
    Nyfors A, Brodthagen H (1970) Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 140(6):345–355PubMedCrossRefGoogle Scholar
  160. 160.
    Ohtsuka T (2008) The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch Dermatol Res 300:545–550PubMedCrossRefGoogle Scholar
  161. 161.
    Orfanos CE, Steigleder GK, Pullmann H, Bloch PH (1979) Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol 59(3):241–244PubMedGoogle Scholar
  162. 162.
    Ortonne JP, Kaufmann R, Lecha M, Goodfield M (2004) Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 209(4):308–313. doi: 10.1159/000080854 PubMedCrossRefGoogle Scholar
  163. 163.
    Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, Wozel G, Lorette G (2006) 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86(1):29–33. doi: 10.1080/00015550510039817 PubMedGoogle Scholar
  164. 164.
    Pacifico A, Daidone R, Peris K (2006) A new formulation of an occlusive dressing containing betamethasone valerate 0.1% in the treatment of mild to moderate psoriasis. J Eur Acad Dermatol Venereol 20(2):153–157. doi: 10.1111/j.1468-3083.2006.01387.x PubMedCrossRefGoogle Scholar
  165. 165.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S (2007) Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 57(2):269–275. doi: 10.1016/j.jaad.2006.12.003 PubMedCrossRefGoogle Scholar
  166. 166.
    Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A (2003) Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 48(1):48–54. doi: 10.1067/mjd.2003.130 PubMedCrossRefGoogle Scholar
  167. 167.
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675–1684. doi: 10.1016/S0140-6736(08)60726-6 PubMedCrossRefGoogle Scholar
  168. 168.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152(6):1304–1312. doi: 10.1111/j.1365-2133.2005.06688.x PubMedCrossRefGoogle Scholar
  169. 169.
    Park YK, Kim HJ, Koh YJ (1988) Combination of photochemotherapy (PUVA) and ultraviolet B (UVB) in the treatment of psoriasis vulgaris. J Dermatol 15(1):68–71PubMedGoogle Scholar
  170. 170.
    Parker S, Coburn P, Lawrence C, Marks J, Shuster S (1984) A randomized double-blind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis. Br J Dermatol 110(2):215–220PubMedCrossRefGoogle Scholar
  171. 171.
    Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291(23):1207–1211PubMedCrossRefGoogle Scholar
  172. 172.
    Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA (1982) Combined methotrexate–ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 7(6):758–762PubMedCrossRefGoogle Scholar
  173. 173.
    Peharda V, Gruber F, Prpic L, Kastelan M, Brajac I (2000) Comparison of mometasone fluroate 0.1% ointment and betamethasone dipropionate 0.05% ointment in the treatment of psoriasis vulgaris. Acta Derm Venereol Croat 8(4):223–226Google Scholar
  174. 174.
    Peroni A, Gisondi P, Zanoni M, Girolomoni G (2008) Balneotherapy for chronic plaque psoriasis at Comano spa in Trentino, Italy. Dermatol Ther 21(Suppl 1):S31–S38. doi: 10.1111/j.1529-8019.2008.00200.x PubMedCrossRefGoogle Scholar
  175. 175.
    Petrozzi JW (1983) Topical steroids and UV radiation in psoriasis. Arch Dermatol 119(3):207–210PubMedCrossRefGoogle Scholar
  176. 176.
    Petzelbauer P, Honigsmann H, Langer K, Anegg B, Strohal R, Tanew A, Wolff K (1990) Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol 123(5):641–647PubMedCrossRefGoogle Scholar
  177. 177.
    Poulin YP (1999) Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 63(1):41–48PubMedGoogle Scholar
  178. 178.
    Prins M, Swinkels OQ, Bouwhuis S, de Gast MJ, Bouwman-Boer Y, van der Valk PG, van de Kerkhof PC (2000) Dithranol in a cream preparation: disperse or dissolve? Skin Pharmacol Appl Skin Physiol 13(5):273–279PubMedGoogle Scholar
  179. 179.
    Prins M, Swinkels OQ, Van de Kerkhof PC, Van der Valk PG (2001) The impact of the frequency of short contact dithranol treatment. Eur J Dermatol 11(3):214–218PubMedGoogle Scholar
  180. 180.
    Radtke MA, Augustin M (2008) Economic considerations in psoriasis management. Clin Dermatol 26(5):424–431. doi: 10.1016/j.clindermatol.2007.10.024 PubMedCrossRefGoogle Scholar
  181. 181.
    Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 200(1):17–24PubMedCrossRefGoogle Scholar
  182. 182.
    Ranjan N, Sharma NL, Shanker V, Mahajan VK, Tegta GR (2007) Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study. J Dermatolog Treat 18(5):295–300. doi: 10.1080/09546630701499291 PubMedCrossRefGoogle Scholar
  183. 183.
    Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1):401–407PubMedCrossRefGoogle Scholar
  184. 184.
    Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6 PubMedCrossRefGoogle Scholar
  185. 185.
    Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145(3):438–445PubMedCrossRefGoogle Scholar
  186. 186.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A (2008) Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 158(3):549–557. doi: 10.1111/j.1365-2133.2007.08236.x PubMedCrossRefGoogle Scholar
  187. 187.
    Richards HL, Fortune DG, Griffiths CE (2006) Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 20(4):370–379PubMedCrossRefGoogle Scholar
  188. 188.
    Richards HL, Fortune DG, O’Sullivan TM, Main CJ, Griffiths CE (1999) Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41(4):581–583PubMedGoogle Scholar
  189. 189.
    Ring J, Kowalzick L, Christophers E, Schill WB, Schopf E, Stander M, Wolff HH, Altmeyer P (2001) Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol 144(3):495–499PubMedCrossRefGoogle Scholar
  190. 190.
    Robertson DB, McCarty JR, Jarratt M (1978) Treatment of psoriasis with 8-methoxypsoralen and sunlight. South Med J 71(11):1345–1349PubMedCrossRefGoogle Scholar
  191. 191.
    Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M (1979) Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1(8114):455–458PubMedCrossRefGoogle Scholar
  192. 192.
    Rosina P, Giovannini A, Gisondi P, Girolomoni G (2009) Microcirculatory modifications of psoriatic lesions during topical therapy. Skin Res Technol 15(2):135–138. doi: 10.1111/j.1600-0846.2008.00336.x PubMedCrossRefGoogle Scholar
  193. 193.
    Salim A, Tan E, Ilchyshyn A, Berth-Jones J (2006) Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 154(6):1169–1174. doi: 10.1111/j.1365-2133.2006.07289.x PubMedCrossRefGoogle Scholar
  194. 194.
    Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S (2007) Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 18(6):361–365. doi: 10.1080/09546630701646156 PubMedCrossRefGoogle Scholar
  195. 195.
    Saurat JH, Geiger JM, Amblard P, Beani JC, Boulanger A, Claudy A, Frenk E, Guilhou JJ, Grosshans E, Merot Y et al (1988) Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177(4):218–224PubMedCrossRefGoogle Scholar
  196. 196.
    Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158(3):558–566. doi: 10.1111/j.1365-2133.2007.08315.x PubMedCrossRefGoogle Scholar
  197. 197.
    Schiener R, Brockow T, Franke A, Salzer B, Peter RU, Resch KL (2007) Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol 143(5):586–596. doi: 10.1001/archderm.143.5.586 PubMedCrossRefGoogle Scholar
  198. 198.
    Schmid-Ott G, Malewski P, Kreiselmaier I, Mrowietz U (2005) Psychosocial consequences of psoriasis—an empirical study of disease burden in 3753 affected people. Hautarzt 56(5):466–472. doi: 10.1007/s00105-005-0906-9 PubMedCrossRefGoogle Scholar
  199. 199.
    Schopf RE, Aust H, Knop J (2002) Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46(6):886–891PubMedCrossRefGoogle Scholar
  200. 200.
    Serwin AB, Chodynicka B (2007) Soluble tumour necrosis factor-alpha receptor type 1 as a biomarker of response to phototherapy in patients with psoriasis. Biomarkers 12(6):599–607. doi: 10.1080/13547500701600597 PubMedCrossRefGoogle Scholar
  201. 201.
    Serwin AB, Wasowicz W, Chodynicka B (2006) Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition 22(9):860–864. doi: 10.1016/j.nut.2006.05.011 PubMedCrossRefGoogle Scholar
  202. 202.
    Shupack JL, Jondreau L, Kenny C, Stiller MJ (1993) Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 186(2):129–132PubMedCrossRefGoogle Scholar
  203. 203.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN (2006) Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol 155(1):160–169. doi: 10.1111/j.1365-2133.2006.07316.x PubMedCrossRefGoogle Scholar
  204. 204.
    Snellman E, Klimenko T, Rantanen T (2004) Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol 84(2):132–137PubMedCrossRefGoogle Scholar
  205. 205.
    Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U (2001) Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 5(4):303–307. doi: 10.1007/s10227-001-0006-0 PubMedCrossRefGoogle Scholar
  206. 206.
    Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9(2):136–139. doi: 10.1046/j.1087-0024.2003.09102.x PubMedCrossRefGoogle Scholar
  207. 207.
    Stinco G, Lautieri S, Valent F, Patrone P (2007) Cutaneous vascular alterations in psoriatic patients treated with cyclosporine. Acta Derm Venereol 87(2):152–154. doi: 10.2340/00015555-0216 PubMedCrossRefGoogle Scholar
  208. 208.
    Svensson AR, Gisslen H, Nordin P, Gios I (1992) A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res Clin Exp 52(3):390–396CrossRefGoogle Scholar
  209. 209.
    Swinkels OQ, Prins M, Kucharekova M, de Boo T, Gerritsen MJ, van der Valk PG, van de Kerkhof PC (2002) Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid. Br J Dermatol 146(4):621–626PubMedCrossRefGoogle Scholar
  210. 210.
    Tabolli S, Alessandroni L, Didona B, Di Pietro C, Gisondi P, Rota L, Sampogna F, Abeni D (2009) A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis. Clin Exp Dermatol 34(3):304–308. doi: 10.1111/j.1365-2230.2008.02932.x PubMedCrossRefGoogle Scholar
  211. 211.
    Taibjee SM, Cheung ST, Laube S, Lanigan SW (2005) Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 153(5):960–966. doi: 10.1111/j.1365-2133.2005.06827.x PubMedCrossRefGoogle Scholar
  212. 212.
    Tausk F, Whitmore SE (1999) A pilot study of hypnosis in the treatment of patients with psoriasis. Psychother Psychosom 68(4):221–225PubMedCrossRefGoogle Scholar
  213. 213.
    Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E (2002) Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology 205(4):383–388PubMedCrossRefGoogle Scholar
  214. 214.
    Thune P, Brolund L (1992) Short- and long-contact therapy using a new dithranol formulation in individually adjusted dosages in the management of psoriasis. Acta Derm Venereol Suppl (Stockh) 172:28–29Google Scholar
  215. 215.
    Torras H, Aliaga A, Lopez-Estebaranz JL, Hernandez I, Gardeazabal J, Quintanilla E, Mascaro JM (2004) A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat 15(2):98–103. doi: 10.1080/09546630410023322 PubMedCrossRefGoogle Scholar
  216. 216.
    Traupe H, Robra BP (2002) Gesundheitsberichterstattung des Bundes, vol Heft 11. Robert-Koch-Institut, BerlinGoogle Scholar
  217. 217.
    Trehan M, Taylor CR (2002) Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 47(5):701–708PubMedCrossRefGoogle Scholar
  218. 218.
    Trott J, Gerber W, Hammes S, Ockenfels HM (2008) The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions. Eur J Dermatol 18(1):55–60. doi: 10.1684/ejd.2008.0311 PubMedGoogle Scholar
  219. 219.
    Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367(9504):29–35. doi: 10.1016/S0140-6736(05)67763-X PubMedCrossRefGoogle Scholar
  220. 220.
    ul Bari A, Iftikhar N, ber Rahman S, Iftikhar N, ber Rahman S (2005) Comparison of PUVA and UVB therapy in moderate plaque psoriasis. J Pak Assoc Dermatol 15:26–31Google Scholar
  221. 221.
    Valbuena MC, Hernandez O, Rey M, Sanchez G, de Quintana LP (2007) Twice- vs. thrice-weekly MPD PUVA in psoriasis: a randomized-controlled efficacy study. Photodermatol Photoimmunol Photomed 23(4):126–129. doi: 10.1111/j.1600-0781.2007.00294.x PubMedCrossRefGoogle Scholar
  222. 222.
    van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ, Olsen L, Revuz J (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138(1):84–89PubMedCrossRefGoogle Scholar
  223. 223.
    van de Kerkhof PC, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragballe K, Larsen FG, Munro CS, Tillman DM (2002) Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 204(3):214–221PubMedCrossRefGoogle Scholar
  224. 224.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J (2008) Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159(5):1177–1185. doi: 10.1111/j.1365-2133.2008.08771.x PubMedGoogle Scholar
  225. 225.
    van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, Damstra R, Oranje AP, de Waard-van der Spek FB, van Neer P, Lijnen RL, Kunkeler AC, van Hees C, Haertlein NG, Hol CW (2006) A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 155(4):800–807. doi: 10.1111/j.1365-2133.2006.07393.x PubMedCrossRefGoogle Scholar
  226. 226.
    van Lingen RG, de Jong EM, Berends MA, Seyger MM, van Erp PE, van de Kerkhof PC (2008) Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T-cell subsets: a pilot study. J Dermatolog Treat 19(5):284–287PubMedCrossRefGoogle Scholar
  227. 227.
    van Lingen RG, Korver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM (2008) Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. Br J Dermatol 159(1):91–96. doi: 10.1111/j.1365-2133.2008.08618.x PubMedCrossRefGoogle Scholar
  228. 228.
    Vella Briffa D, Rogers S, Greaves MW, Marks J, Shuster S, Warin AP (1978) A randomized, controlled clinical trial comparing photochemotherapy with dithranol in the initial treatment of chronic plaque psoriasis. Clin Exp Dermatol 3(4):339–347PubMedCrossRefGoogle Scholar
  229. 229.
    Vena GA, Cassano N, Agnusdei CP, Bellini M, Calabretta S, Centofani S, Cervadoro G, Coviello C, Curia S, Dattola S, de Caro C, del Brocco L, Donato L, Favero L, Ferrari A, Gianfaldoni R, Liguori G, Loconsole F, Lopreiato R, Malara G, Massimino SD, Nannipieri A, Pettinato M, Postiglione D, Postorioni C, Pronesti ME, Provenzano E, Puglisi Guerra A, Ricciuti F, Ruggiero G, Scudero A, Spitaleri S, Trinca Armati F, Valenti G, Vernaci R, Verrina F, Zagni GF, Zappala F (2005) Treatment of psoriasis vulgaris with calcipotriol betamethasone dipropionate combination followed by calcipotriol and assessment of the adjuvant basic use of urea-based emollients. Eur J Inflamm 3(1):37–41Google Scholar
  230. 230.
    Vena GA, Cassano N, Loconsole F, Malara G, Sciarrone C, Puglisi Guerra A (2006) Sequential treatment of psoriasis with infliximab followed by cyclosporin. Preliminary results of an open-label prospective study. G Ital Dermatol Venereol 141:221–225Google Scholar
  231. 231.
    Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Pezza M, M DA, Vernaci R, Miracapillo A, Valenti G, Cassano N (2009) A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopathol Pharmacol 22(1):227–233Google Scholar
  232. 232.
    Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S (2006) Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 212(3):235–237. doi: 10.1159/000091250 PubMedCrossRefGoogle Scholar
  233. 233.
    Vongthongsri R, Konschitzky R, Seeber A, Treitl C, Honigsmann H, Tanew A (2006) Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. J Am Acad Dermatol 55(4):627–631. doi: 10.1016/j.jaad.2006.05.024 PubMedCrossRefGoogle Scholar
  234. 234.
    Weinstein GD, Frost P (1971) Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103(1):33–38PubMedCrossRefGoogle Scholar
  235. 235.
    Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS (2003) Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 48(5):760–767. doi: 10.1067/mjd.2003.103 PubMedCrossRefGoogle Scholar
  236. 236.
    Weston WL, Fennessey PV, Morelli J, Schwab H, Mooney J, Samson C, Huff L, Harrison LM, Gotlin R (1988) Comparison of hypothalamus–pituitary–adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 90(4):532–535PubMedCrossRefGoogle Scholar
  237. 237.
    White S, Vender R, Thaci D, Haverkamp C, Naeyaert J-M, Foster R, Martinez Escribano JA, Cambazard F, Bibby A (2006) Use of calcipotriene cream (Dovonex Cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex). Am J Clin Dermatol 7(3):177–184PubMedCrossRefGoogle Scholar
  238. 238.
    Yones SS, Palmer RA, Garibaldinos TT, Hawk JL (2006) Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 142(7):836–842. doi: 10.1001/archderm.142.7.836 PubMedCrossRefGoogle Scholar
  239. 239.
    Yoon HS, Youn JI (2007) A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. J Dermatolog Treat 18(5):286–290. doi: 10.1080/09546630701418747 PubMedCrossRefGoogle Scholar
  240. 240.
    Youssef RM, Mahgoub D, Mashaly HM, El-Nabarawy E, Samir N, El-Mofty M (2008) Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed 24(5):256–259. doi: 10.1111/j.1600-0781.2008.00371.x PubMedCrossRefGoogle Scholar
  241. 241.
    Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S (2008) The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 88(5):495–501. doi: 10.2340/00015555-0511 PubMedCrossRefGoogle Scholar
  242. 242.
    Zaghloul SS, Goodfield MJ (2004) Objective assessment of compliance with psoriasis treatment. Arch Dermatol 140(4):408–414PubMedCrossRefGoogle Scholar
  243. 243.
    Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P (2007) An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 21(4):466–472. doi: 10.1111/j.1468-3083.2006.01913.x PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • A. Nast
    • 1
    Email author
  • W. H. Boehncke
    • 2
  • U. Mrowietz
    • 3
  • H. M. Ockenfels
    • 4
  • S. Philipp
    • 5
  • K. Reich
    • 6
  • T. Rosenbach
    • 7
  • A. Sammain
    • 1
  • M. Schlaeger
    • 8
  • M. Sebastian
    • 9
  • W. Sterry
    • 10
  • V. Streit
    • 11
  • M. Augustin
    • 12
  • R. Erdmann
    • 1
  • J. Klaus
    • 13
  • J. Koza
    • 13
  • S. Müller
    • 14
  • H. D. Orzechowski
    • 15
  • S. Rosumeck
    • 1
  • G. Schmid-Ott
    • 16
  • T. Weberschock
    • 2
  • B. Rzany
    • 1
  1. 1.Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Venerologie und AllergologieCharité-Universitätsmedizin BerlinBerlinGermany
  2. 2.Zentrum der Dermatologie und VenerologieKlinikum der Johann Wolfgang Goethe UniversitätFrankfurt am MainGermany
  3. 3.Klinik für Dermatologie, Venerologie, AllergologieUniversitätsklinikum Schleswig–HolsteinKielGermany
  4. 4.Haut-u. AllergieklinikHanauGermany
  5. 5.Psoriasisstudienzentrum Klinik für Dermatologie, Venerologie und AllergologieCharité-Universitätsmedizin BerlinBerlinGermany
  6. 6.Dermatologikum HamburgHamburgGermany
  7. 7.OsnabrückGermany
  8. 8.OldenburgGermany
  9. 9.MahlowGermany
  10. 10.Klinik für Dermatologie, Venerologie und AllergologieCharité-Universitätsmedizin BerlinBerlinGermany
  11. 11.BuchholzGermany
  12. 12.Klinik und Poliklinik für Dermatologie und VenerologieUniversitätsklinikum Hamburg-EppendorfHamburgGermany
  13. 13.Deutscher Psoriasis Bund e.VHamburgGermany
  14. 14.RavensteinGermany
  15. 15.Institut für Klinische Pharmakologie und ToxikologieCharité-Universitätsmedizin BerlinBerlinGermany
  16. 16.Berolina KlinikLöhneGermany

Personalised recommendations